{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:34:50Z","timestamp":1781602490607,"version":"3.54.5"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["mdconsult.com","theclinics.com","labmed.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.cll.2014.06.011","type":"journal-article","created":{"date-parts":[[2014,7,21]],"date-time":"2014-07-21T14:16:35Z","timestamp":1405952195000},"page":"519-536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment and Long-Term Management of Venous Thromboembolism"],"prefix":"10.1016","volume":"34","author":[{"given":"Ahmed","family":"Al-Badri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex C.","family":"Spyropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cll.2014.06.011_bib1","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1185\/03007995.2013.803462","article-title":"Venous thromboembolism management: where do novel anticoagulants fit?","volume":"29","author":"Spyropoulos","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cll.2014.06.011_bib2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1538-7836.2012.04629.x","article-title":"A\u00a0conceptual framework for two phases of anticoagulant treatment of venous thromboembolism","volume":"10","author":"Kearon","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.cll.2014.06.011_bib3","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/archinte.160.6.761","article-title":"Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cll.2014.06.011_bib4","doi-asserted-by":"crossref","first-page":"I-22","DOI":"10.1161\/01.CIR.0000078464.82671.78","article-title":"Natural history of venous thromboembolism","volume":"107","author":"Kearon","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cll.2014.06.011_bib5","doi-asserted-by":"crossref","first-page":"454S","DOI":"10.1378\/chest.08-0658","article-title":"Antithrombotic therapy for venous thromboembolic disease. ACCP Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Kearon","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.cll.2014.06.011_bib6","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1046\/j.1538-7836.2004.00698.x","article-title":"Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor","volume":"2","author":"Kearon","year":"2004","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.cll.2014.06.011_bib7","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1046\/j.1365-2796.2000.00631.x","article-title":"Comparison of long versus short duration of anticoagulant therapy after a first episode of venous thromboembolism: a meta-analysis of randomized, controlled trials","volume":"247","author":"Pinede","year":"2000","journal-title":"J\u00a0Intern Med"},{"issue":"Suppl 2","key":"10.1016\/j.cll.2014.06.011_bib8","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: ACCP Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.cll.2014.06.011_bib9","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/archinte.160.6.769","article-title":"Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors","volume":"160","author":"Hansson","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cll.2014.06.011_bib10","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1161\/01.CIR.103.20.2453","volume":"103","author":"Pinede","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.cll.2014.06.011_bib11","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1056\/NEJM199506223322501","article-title":"Duration of Anticoagulation Trial Study Group. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism","volume":"332","author":"Schulman","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cll.2014.06.011_bib12","doi-asserted-by":"crossref","first-page":"d3036","DOI":"10.1136\/bmj.d3036","article-title":"Influence of preceding duration of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping therapy: analysis of individual participants\u2019 data from seven trials","volume":"342","author":"Boutitie","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.cll.2014.06.011_bib13","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cll.2014.06.011_bib14","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa030104","article-title":"THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran","volume":"349","author":"Schulman","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 8A","key":"10.1016\/j.cll.2014.06.011_bib15","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.1016\/j.amjmed.2005.06.006","article-title":"Anticoagulants in the treatment of deep vein thrombosis","volume":"118","author":"Merli","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.cll.2014.06.011_bib16","doi-asserted-by":"crossref","first-page":"866","DOI":"10.2146\/ajhp070408","article-title":"Initial management of deep venous thrombosis in the outpatient setting","volume":"65","author":"Groce","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.cll.2014.06.011_bib17","doi-asserted-by":"crossref","first-page":"298","DOI":"10.18553\/jmcp.2000.6.4.298","article-title":"Outcomes analyses of the outpatient treatment of venous thromboembolic disease using the low-molecular weight heparin enoxaparin in a managed care organization","volume":"6","author":"Spyropoulos","year":"2000","journal-title":"J\u00a0Manag Care Pharm"},{"key":"10.1016\/j.cll.2014.06.011_bib18","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1164\/rccm.200506-862OC","article-title":"Derivation and validation of a prognostic model for pulmonary embolism","volume":"172","author":"Aujesky","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cll.2014.06.011_bib19","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archinternmed.2010.199","article-title":"Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism","volume":"170","author":"Jimenez","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cll.2014.06.011_bib20","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1055\/s-0037-1614065","article-title":"Predicting adverse outcome in patients with acute pulmonary embolism: a risk score","volume":"84","author":"Wicki","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cll.2014.06.011_bib21","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1093\/eurheartj\/ehn310","article-title":"The task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Guidelines on the diagnosis and management of acute pulmonary embolism","volume":"29","author":"Torbicki","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cll.2014.06.011_bib22","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1111\/j.1538-7836.2011.04459.x","article-title":"Comparison of two prognostic models for acute pulmonary embolism: clinical vs. right ventricular dysfunction-guided approach","volume":"9","author":"Vanni","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.cll.2014.06.011_bib23","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1378\/chest.11-1355","article-title":"A\u00a0strategy combining imaging and laboratory biomarkers in comparison with a simplified clinical score for risk stratification of patients with acute pulmonary embolism","volume":"141","author":"Lankeit","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.cll.2014.06.011_bib24","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/j.1538-7836.2010.03831.x","article-title":"Out of hospital treatment of acute pulmonary embolism in patients with a low NT-proBNP level","volume":"8","author":"Agterof","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.cll.2014.06.011_bib25","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.thromres.2012.03.010","article-title":"LR-PED rule: low risk pulmonary embolism decision rule: a new decision score for low risk pulmonary embolism","volume":"130","author":"Barra","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.cll.2014.06.011_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(11)60824-6","article-title":"Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomized, non-inferiority trial","volume":"378","author":"Aujesky","year":"2011","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.cll.2014.06.011_bib27","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1001\/archinte.162.22.2521","article-title":"The uncertain role of thrombolytic therapy in the treatment of pulmonary embolism","volume":"162","author":"Dalen","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cll.2014.06.011_bib28","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.humpath.2006.11.017","article-title":"Pulmonary thromboendarterectomy: a clinicopathologic study of 200 consecutive pulmonary thromboendarterectomy cases in one institution","volume":"38","author":"Bernard","year":"2007","journal-title":"Hum Pathol"},{"key":"10.1016\/j.cll.2014.06.011_bib29","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cll.2014.06.011_bib30","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"The Hokusai-VTE Investigators","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cll.2014.06.011_bib31","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cll.2014.06.011_bib32","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cll.2014.06.011_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-125-1-199607010-00001","article-title":"The long-term clinical course of acute deep venous thrombosis","volume":"125","author":"Prandoni","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cll.2014.06.011_bib34","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMoa1210384","article-title":"Low-dose aspirin for preventing recurrent venous thromboembolism","volume":"367","author":"Brighton","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cll.2014.06.011_bib35","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMoa1114238","article-title":"Aspirin for preventing the recurrence of venous thromboembolism","volume":"366","author":"Becattini","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cll.2014.06.011_bib36","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa035029","article-title":"Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism","volume":"348","author":"Ridker","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cll.2014.06.011_bib37","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa035422","article-title":"Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism","volume":"349","author":"Kearon","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.cll.2014.06.011_bib38","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(08)70149-9","article-title":"Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis","volume":"9","author":"Noble","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cll.2014.06.011_bib39","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","article-title":"Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer","volume":"119","author":"Hull","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.cll.2014.06.011_bib40","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1055\/s-2008-1047561","article-title":"Update in the treatment of venous thromboembolism","volume":"29","author":"Garcia","year":"2008","journal-title":"Semin Respir Crit Care Med"},{"issue":"Suppl 2","key":"10.1016\/j.cll.2014.06.011_bib41","first-page":"731","article-title":"Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism [abstract O-TH-033]. ISTH 2011","volume":"9","author":"Schulman","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"issue":"Suppl 2","key":"10.1016\/j.cll.2014.06.011_bib42","first-page":"731","article-title":"Dabigatran versus placebo for extended maintenance therapy of venous thromboembolism [abstract 037]. ISTH 2011","volume":"9","author":"Schulman","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.cll.2014.06.011_bib43","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1586\/erc.11.62","article-title":"Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study)","volume":"9","author":"Romualdi","year":"2011","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.cll.2014.06.011_bib44","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 20","key":"10.1016\/j.cll.2014.06.011_bib45","first-page":"S1034","article-title":"Outpatient-based treatment protocols in the management of venous thromboembolic disease","volume":"6","author":"Spyropoulos","year":"2000","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.cll.2014.06.011_bib46","unstructured":"Pradaxa (Dabigatran) [Package Insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 2012."},{"key":"10.1016\/j.cll.2014.06.011_bib47","unstructured":"Xarelto (Rivaroxaban) [Package Insert]. Titusville, NJ: Janssen Pharmaceuticals; 2011."},{"key":"10.1016\/j.cll.2014.06.011_bib48","unstructured":"Eliquis (Apixaban) [Prescribing Information]. Princeton, NJ: Bristol-Myers Squibb Company; 2012."},{"key":"10.1016\/j.cll.2014.06.011_bib49","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0091270009351883","article-title":"Clinical safety, tolerability, pharmacokinetics and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers","volume":"50","author":"Ogata","year":"2010","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.cll.2014.06.011_bib50","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"Buller","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cll.2014.06.011_bib51","doi-asserted-by":"crossref","unstructured":"Schulman S, Kakkar AK, Schellong SM, et\u00a0al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II) [abstract 205]. American Society of Hematology 2011 Annual Meeting. San Diego. 2011.","DOI":"10.1182\/blood.V118.21.205.205"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271214000559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271214000559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T12:44:57Z","timestamp":1598100297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271214000559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0272271214000559"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2014.06.011","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment and Long-Term Management of Venous Thromboembolism","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2014.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}